A review of minodronic acid hydrate for the treatment of osteoporosis

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 185-189

  Tanishima, Shinji ^a   Morio, Yasuo ^a  

^a Misasa Onsen Hospital   (Japan)

Author keywords

Bisphosphonate; Minodronic acid hydrate; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; ETIDRONIC ACID; MINODRONIC ACID; OSTEOCALCIN; PLACEBO;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE METABOLISM; BONE STRENGTH; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG MECHANISM; FEMALE; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; JAPAN; LUMBAR SPINE; MULTICENTER STUDY (TOPIC); OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

BISPHOSPHONATE; MINODRONIC ACID HYDRATE; OSTEOPOROSIS; TREATMENT;

AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES;

EID: 84873971956     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S23927     Document Type: Review

References (22)

1. Raisz L. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318-3325.
2. Ettinger B, Black DM, Nevitt MC, et al. Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1992;7(4):449-456.
3. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7): 556-561.
4. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761-1767.
5. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11(4):219-227.
6. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 4th ed. San Diego: Academic Press; 2000.
7. Tanaka M, Mori H, Shimizu K, et al. Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis. Nihon Yakurigaku Zasshi. 2009;134(3):149-157. Japanese.
8. Sorbera LA, Capstaner J, Leeson PA. Minodronic acid. Drugs Future. 2002;27:935-941.
9. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-242.
10. Tanishima S, Kishimoto Y, Fukata S, Mizumura H, Hagino H, Teshima R. Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis. Mod Rheumatol. 2007;17(3):198-205.
11. Kubo T, Shimose S, Matsuo T, Fujimori J, Ochi M. Minodronate for the treatment of osteoporosis. Drugs Today (Barc). 2010;46(1):33-37.
12. Hagino H, Nishizawa Y, Sone T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009;44(6):1078-1084.
13. Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int. 2009;20(8):1429-1437.
14. Ito M, Sone T, Fukunaga M. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab. 2010;28(3):334-341.
15. Okazaki R, Hagino H, Ito M, et al. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int. 2012;23(6):1737-1745.
16. Ross PD, Fujiwara S, Huang C, et al. Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol. 1995;24(6):1171-1177.
17. Mori H, Nisshizawa Y, Taketani Y. A randomized controlled trial with ONO-5290 in Japanese patients with postmenopousal osteoporosis [abstract]. J Bone Miner Res. 2002;17 Suppl 1:S471.
18. Yamane I, Hagino H, Okano T, Enokida M, Yamasaki D, Teshima R. Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis. Arthritis Rheum. 2003;48(6):1732-1741.
19. Mori H, Kayasuga R, Tanaka M, et al. Inhibitory effect of minodronic acid on bone resorption in vitro and in vivo-comparison with risedronate and alendronate. Clin Pharmacol Ther. 2008;18:S19-S32.
20. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30(9):755-763.
21. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12(1):1-12.
22. Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5(10):475-482.